Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 120

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 120
---
 holds 60,136 non-voting ordinary shares and Life Sciences directly holds 674,261 non-voting ordinary shares, which may be converted into ordinary shares, subject to the Baker Beneficial Ownership Limitation set forth below, on a one-for-one basis. Finally, 667 and Life Sciences hold notes described above that may be converted, without application of the Baker Beneficial Ownership Limitation (as defined below), into 134,789 ADS and 1,449,225 ADS, respectively. The notes and the non-voting ordinary shares are only convertible to the extent that after giving effect to such conversion the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 4.99% of the outstanding ordinary shares, including ordinary shares in the form of ADS (“Baker Beneficial Ownership Limitation”), and the number of ordinary shares reported as beneficially owned gives effect to the Baker Beneficial Ownership Limitation. By written notice to the Issuer, the Baker Funds may from time to time increase or decrease the Baker Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. |

| (4) | The number of securities in column “Maximum Number of Ordinary Shares Registered Hereunder for Sale” represents all of the ordinary shares that the selling shareholders may offer and sell from time to time under this prospectus, without regard to the Baker Beneficial Ownership Limitation. |

S-66

TABLE OF CONTENTS

PLAN OF DISTRIBUTION We are registering the notes and the note conversion ADSs to permit the resale by the selling securityholders from time to time of up to $150,000,000 aggregate principal amount of notes, including the note conversion ADSs issuable upon conversion thereof. We will not receive any of the proceeds from the sale by the selling securityholders of the notes or any note conversion ADSs. The selling securityholders will bear the costs associated with this registration of the notes and the note conversion ADSs. There can be no assurance that the selling securityholders will sell any or all of the notes or any note conversion ADSs registered pursuant to this prospectus supplement. The selling securityholders, which, as used herein, includes donees, pledgees, transf